
The humanized monoclonal antibody JSP191 showed an 100% complete donor chimerism and resulted in no treatment-related adverse events when administered to patients with Fanconi anemia.

The humanized monoclonal antibody JSP191 showed an 100% complete donor chimerism and resulted in no treatment-related adverse events when administered to patients with Fanconi anemia.

Melhem Solh, MD, discusses his research on post-transplant outcomes of patients with TP53-mutant acute myeloid leukemia and myelodysplastic syndrome.

In an interview with Targeted Oncology following the tweet chat, Cyrus M. Khan, MD, discussed the emerging and recent data he thinks could influence the case we discussed.

Based on preclinical studies which have shown the clinical benefit of Olvi-Vec, a phase 3 trial evaluating the agent in combination with platinum-doublet chemotherapy and bevacizumab has commenced in patients with platinum-resistant/refractory ovarian cancer.

Pain is a clinical challenge for many oncology patients and clinicians, and there's a growing body of evidence showing that integrative therapies can be useful in pain management, according to Heather Greenlee, ND, PhD.

Pertuzumab plus trastuzumab and chemotherapy remains the standard of care for HER2-positive breast cancer, after the addition of atezolizumab did not benefit responses in the Impassion050 study.

A 5-year overall survival analysis led the FDA to question duvelisib for relapsed or refractory chronic lymphocytic leukemia. ODAC members voted that the benefit-risk profile of the drug is not favorable.

Due to the potential detriment in overall survival, its failure to demonstrate a progression-free survival benefit, and the lack of a known appropriate dose, ODAC has voted that melphalan flufenamide is not favorable in relapsed/refractory multiple myeloma.

Based on the efficacy, toxicity, dose-optimization, and lack of confirmatory data for poziotinib in HER2 exon 20 insertion-positive non–small cell lung cancer, ODAC has voted that the drug has an unfavorable risk/benefit profile.

Jonathan E. Rosenberg, MD, discusses what the frontline treatment landscape for metastatic urothelial cancer currently looks like.

Following a report of impressive 2-year follow-up data, the FDA has granted a regular approval to selpercatinib.

Alexander Drilon, MD, discusses what community oncologists should know about testing for NTRK gene fusions in patients with solid tumors.

Enrollment has begun in the phase 1b trial examining PY159 alone and in combination with pembrolizumab in patients with unresectable and/or metastatic solid tumors that are refractory or relapsed to standard of care.

The FDA has granted approval to Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients.

Distinguishing on current imaging between disease progression and pseudo progression in patients with glioblastoma is one of the most difficult clinical problems, according to Manmeet Ahluwalia, MD and Pallavi Tiwari, PhD.

Findings of the phase 2 LCMC3 trial of atezolizumab in untreated, resectable, stage IB–IIIB non–small cell lung cancer show anti-PD-L1 monotherapy to be effective in this patient population.

Celsion Corporation announced it had reached enrollment of 110 patients for the OVATION 2 trial of GEN-1 plus neoadjuvant chemotherapy for patients with advanced ovarian cancer.

With extended follow-up, selpercatinib has maintained its efficacy and safety in patients with RET fusion-positive non-small cell lung cancer.

Approval has been granted to aprepitant injectable emulsion by the FDA for the prevention of postoperative nausea and vomiting in adult patients.

William J. Gradishar, MD, discusses the questions ongoing studies are looking to answer in the breast cancer space.

Christopher J. Melani, MD, discusses the combination investigated in the ViPOR study of patients with relapsed/refractory or untreated mantle cell lymphoma.

In an interview with Targeted Oncology, Jonathan Rosenberg, MD, further discussed the background and results of the EV-103 study in patients with locally advanced metastatic urothelial cancer.

Nearly all patients with HR-positive breast cancer are treated with endocrine therapy, yet Black women are 4 times more likely to die of this disease compared with White women.

Andreana Holowatyj, PhD, MSCI, discusses the rationale for her research on the growing increase of early-onset appendiceal cancer in the United States.

A patient with estrogen receptor positive, HER2-negative metastatic breast cancer enrolled in the phase 2 ELAINE 1 trial demonstrated a durable complete response when treated with lasofoxifene.

Robust and durable antitumor activity continues to be shown with pembrolizumab in patients with microsatellite instability-high or mismatch repair-deficient advanced endometrial cancer.

Adam Cohen, MD, discusses the current FDA-approved BCMA-directed therapies in the multiple myeloma space and the clinical data supporting each agent.

In the phase 3 CheckMate-76K study, adjuvant nivolumab administered to patients with stage IIB/C melanoma resulted in prolonged recurrence-free survival compared with placebo.

In an interview with Targeted Oncology, Matthew Matasar, MD, discusses background information on the ongoing VITALIZE trial of maveropepimut-S in patients with diffuse large B-cell lymphoma.

In a retrospective analysis of 115 patients with relapsed/refractory multiple myeloma who progressed after therapy on a bispecific antibody, researchers found that the myeloma patients can be salvaged with sequential T-cell redirection therapy.